For many patients, this gentler approach can reduce common side effects like gastrointestinal discomfort while still improving metabolic health
A 2021 study identified a putative beta-arrestin "superagonist" of the ghrelin receptor, showing that biased agonism at this receptor could produce functionally distinct outcomes depending on which signaling pathway is preferentially activated
Veit, J., Hakim, R., Jadi, M
doi: 10.1371/journal.pone.0047936 27 LiJ.ZhengJ.WangS.LauH
Its diabetes drug Mounjaro has seen robust growth in the ~18 months that it has been on the market
In 2024 Blue Cross Blue Shield of Michigan informed members and physicians about a change in coverage for GLP-1s.On the surface, GLP-1s promise weight loss, lower blood pressure and a reduced risk of heart and kidney disease, according to the Cleveland Clinic